# Project State

## Project Reference

See: .planning/PROJECT.md (updated 2026-04-11)

**Core value:** Every policy question answered must include source-backed evidence from loaded policy documents. No evidence, no answer.
**Current focus:** Phase 3: Hybrid Q&A Engine

## Current Position

Phase: 3 of 4 (Hybrid Q&A Engine)
Plan: 0 of TBD
Status: Phase 2 complete; ready to discuss/plan Phase 3
Last activity: 2026-04-15 — Phase 2 executed

Progress: [█████░░░░░] 50%

## Performance Metrics

**Velocity:**
- Total plans completed: 4
- Average duration: 5.75 minutes
- Total execution time: 0.38 hours

**By Phase:**

| Phase | Plans | Total | Avg/Plan |
|-------|-------|-------|----------|
| Phase 01 | 2 | 7 min | 3.5 min |
| Phase 02 | 2 | 16 min | 8 min |

**Recent Plans:**

| Phase 01 P01 | 2 min | 2 tasks | 7 files |
| Phase 01 P02 | 5 | 3 tasks | 3 files |
| Phase 02 P01 | 8 min | 2 tasks | 4 files |
| Phase 02 P02 | 8 min | 2 tasks | 4 files |

## Accumulated Context

### Decisions

Decisions are logged in PROJECT.md Key Decisions table.
Recent decisions affecting current work:

- MCP over A2A: Prompt Opinion MCP integration is the hackathon requirement; existing codebase already uses MCP
- Build on existing codebase: Significant MCP/policy infrastructure already built; faster than starting fresh
- Hybrid Q&A (deterministic + LLM): Pure deterministic misses complex questions; pure LLM risks hallucination; hybrid balances both
- Two documents only: BCBS NC + Cigna sufficient to prove cross-payer comparison; keep scope tight for hackathon
- [Phase 01]: Optional schema fields for backward compatibility with RA policies
- [Phase 01]: Added FDA biosimilar suffix variants to drug alias system
- [Phase 01-02]: BCBS NC requires FDA MedWatch form for non-preferred bevacizumab products
- [Phase 01-02]: Cigna requires trial of ALL three rituximab biosimilars before brand Rituxan
- [Phase 02-01]: Deterministic tools use a standard response envelope: answer, structured_result, evidence, confidence
- [Phase 02-02]: Single-payer comparison results are allowed, but are marked MEDIUM confidence with a partial-data note

### Pending Todos

None yet.

### Blockers/Concerns

None yet.

## Session Continuity

Last session: 2026-04-17 (discuss-phase)
Stopped at: Phase 3 context gathered
Resume file: .planning/phases/03-hybrid-q-a-engine/03-CONTEXT.md
